Therapeutic potential of mesenchymal stem cells producing interferon-α in a mouse melanoma lung metastasis model

Stem Cells

Volumn 26, Issue 9, 2008, Pages 2332-2338

  Ren, Changchun ^a   Kumar, Sanjay ^a   Chanda, Diptiman ^a   Chen, Jian ^b   Mountz, John D ^b   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Adeno associated virus; Bone marrow stromal cells; Ex vivo gene transfer; Interferon

Indexed keywords

ALPHA INTERFERON; GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO GENE TRANSFER; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MELANOMA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; DEPENDOVIRUS; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 6; ANIMALIA; MUS;

EID: 55049094527     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0084     Document Type: Article

References (38)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
2. Friedenstein AJP, Petrokova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966;16:381-390.
3. Barry FP, Murphy JM. Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568-584.
4. Studeny M, Marini, Frank C et al. Bone Marrow-derived mesenchymal stem cells as vehicles for interferon-β: Delivery into tumors. Cancer Res 2002;62:3603-3608.
5. Kassem M, Kristiansen M, Abdallah BM. Mesenchymal stem cells: Cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol 2004;95:209-214.
6. Pereboeva L, Curiel DT. Cellular vehicles for cancer gene therapy: Current status and future potential. Biodrugs 2004;18:361-385.
7. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-3318.
8. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603.
9. Bissell MJ, Radisky D. Putting tumors in context. Nat Rev Cancer 2001;1:46-54.
10. Ben-Baruch A. Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: Reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003;5:31-36.
11. Pestka S, Langer JA, Zoon KC et al. Interferons and their actions. Annu Rev Biochem 1987;56:727-777.
12. Borden EC. Interferons: Pleiotropic cellular modulators. Clin Immunol Immunopathol 1992;62:S18-24.
13. Mecchia M, Matarrese P, Malorni W et al. Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: Implications for new therapeutic strategies with IFN-alpha. Gene Ther 2000;7:167-179.
14. Heller LC, Ingram SF, Lucas ML et al. Effect of electrically mediated intratumor and intramuscular delivery of a plasmid encoding IFN alpha on visible B16 mouse melanomas. Technol Cancer Res Treat 2002;1:205-209.
15. Papageorgiou A, Kamat A, Benedict WF et al. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006;5:3032-3041.
16. Zhu Y, Tibensky I, Schmidt J et al. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 2008;31:28-33.
17. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-857.
18. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;355:51-65.
19. Garrison M, Nathanson L. Prognosis and staging in melanoma. Semin Oncol 1996;23:725-733.
20. Avril MF, Charpentier P, Margulis A et al. Regression of primary melanoma with metastases. Cancer 1992;69:1377-1381.
21. Grimm D, Kern A, Rittner K et al. Novel tools for production and purification of recombinant adeno associated virus vectors. Hum Gene Ther 1998;9:2745-2760.
22. Zolotukhin S, Byrne BJ, Mason E et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
23. Ponnazhagan S, Mahendra G, Kumar S et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: Long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004;64:1781-1787.
24. Lens M. Cutaneous melanoma: Interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Dermatol Ther 2006;19:9-18.
25. Koç ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of tautologies-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
26. Koç ON, Day J, Nieder M et al. Allogenic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
27. Lazarus HM, Koc ON, Devine SM et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cell and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11:389-398.
28. Ryan JM, Barry FP, Murphy JM et al. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005;2:8.
29. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000;28:382-390.
30. Tsuda H, Wada T, Ito Y et al. Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol Ther 2003;7:354-365.
31. Lee K, Majumdar MK, Buyaner D et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 2001;3:857-866.
32. Sleijfer S, Bannink M, Van Gool AR et al. Side effects of interferon-alpha therapy. Pharm World Sci 2005;27:423-431.
33. Van Gool AR, Kruit WH, Engels FK et al. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003;25:11-20.
34. Moschos SJ, Odoux C, Land SR et al. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: A novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 2007;17:193-200.
35. Hutchins LF, Moon J, Clark JI et al. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer 2007;110:2269-2275.
36. Conill C, Jorcano S, Domingo-Domènech J et al. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res 2007;17:304-309.
37. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: Current status and future directions. Vaccine 2007;25(suppl 2):B4-B16.
38. Fushimi T, O'Connor TP, Crystal R. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth. Cancer Res 2006;66:3513-3522.